(12) **Translation of European patent specification**

(11) **NO/EP 2552920 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 487/04 (2006.01)
A61K 31/495 (2006.01)
A61P 25/00 (2006.01)
A61P 29/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.07.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.03.15
(86)	European Application Nr.	11711922.2
(86)	European Filing Date	2011.04.04
(87)	The European Application's Publication Date	2013.02.06
(30)	Priority	2010.04.02, EP, 10305343 2010.09.01, US, 379028 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	OGEDA SA, Rue Adrienne Bolland 47, 6041 Charleroi, BE-Belgia
(72)	Inventor	HOVEYDA, Hamid, Rue Meyerbeer 72, B-1190 Bruxelles, BE-Belgia ROY, Marie-Odile, 233, rue de Charenton, 75012 Paris, FR-Frankrike FRASER, Graeme Lovat, Rue Bois des Conins 19A, 1470 Bousval, BE-Belgia DUTHEUIL, Guillaume, Rue Joseph Debehogne 19, B-5020 Vedrin, BE-Belgia
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, DK-1260 KØBENHAVN K, Danmark

(54) Title **NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS**

(56) References Cited:

EP-A1- 2 085 398
WO-A2-2006/120478
WO-A2-2007/138351
US-A1- 2008 275 052
US-A1- 2008 318 935
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 October 2008 (2008-10-13), XP002597351, retrieved from STN Database accession no. 1060453-21-5
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 September 2009 (2009-09-18), XP002597352, retrieved from STN Database accession no. 1185553-59-6
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 24 October 2008 (2008-10-24), XP002597353, retrieved from STN Database accession no. 1065517-25-0
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 October 2008 (2008-10-13), XP002597354, retrieved from STN Database accession no. 1060482-62-3
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 24 October 2008 (2008-10-24), XP002597355, retrieved from STN Database accession no. 1065547-14-9

DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 September 2009 (2009-09-18), XP002597356, retrieved from STN Database accession no. 1185694-78-3
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 October 2008 (2008-10-27), XP002597357, retrieved from STN Database accession no. 1066941-41-0
BOTTOMLEY, M. J. ET AL: "Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 26 September 2008 (2008-09-26), pages 26694-26704, XP002597358, DOI: 10.1074/jbc.M803514200
MURALI DHAR, T.G. ET AL: "Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 21 July 2007 (2007-07-21), pages 5019-5024, XP002597359,

Patentkrav

1. Forbindelse med formel I:



I

og farmasøytisk akseptable salter og solvater derav, hvori

Ar[1] er en 5- til 6-leddet aryl- eller heteroarylgruppe, 3 til 6-leddet sykloalkylgruppe, en 3- til 6-leddet heterosyklylgruppe eller en C3-C6-alkylgruppe, idet hver av aryl-, heteroaryl-, sykloalkyl- eller heterosyklylgruppene eventuelt substitueres med én eller flere gruppe(r) valgt fra halo, cyano, alkyl, haloalkyl, sykloalkyl, heteroalkyl, heterosyklyl, aryl, aralkyl, heteroaryl, hydroksyl, alkoksy, haloalkoksy, alkoksyalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, karbamoyl, alkylkarbamoyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, eller to substituenter som danner en alkylendioksy- eller en haloalkylendioksygruppe, eller to substituenter som danner en sykloalkyl- eller heterosykloalkylrest sammen med sykloalkyl- eller heterosykloalkylgruppen de er festet til, eller sammensmeltet til aryl-, heteroaryl-, sykloalkyl- eller heterosykloalkylgruppen kan være én eller flere arylrester, idet hver av substituentene eventuelt substitueres med én eller flere ytterligere substituent(er) valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy, heterosyklyl, aryl, heteroaryl, aryloksyheteroaryloksy;

L[1] er karbonyl;

R[1] er H, en C_1-C_4 alkyl-, aryl- eller aralkylgruppe, idet hver av alkyl-, aryl- eller aralkylgruppene eventuelt substitueres med én eller flere grupper valgt fra halo eller hydroksyl;

R[1'] er H eller en C_1-C_4 -alkylgruppe;

R[2] er H eller en C_1-C_4 -alkylgruppe;

R[2'] er H eller en C_1-C_4 -alkylgruppe;

R[3] er H eller en C_1-C_4 -alkylgruppe eventuelt substituert med en hydroksy;

R[3'] er H eller en C_1-C_4 -alkylgruppe;

X[1] og **X[2]** er N;

L[2] er en enkeltbinding eller karbonyl,

Ar[2] er en 5- til 6-leddet aryl- eller heteroarylgruppe, idet hver av aryl- eller heteroarylgruppene eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, hydroksyalkyl, haloalkyl, sykloalkyl, heteroalkyl, heterosyklyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, hydroksyl, alkoksy, haloalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, acylamino, karbamoyl, alkylkarbamoyl, karbamoylalkyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, arylsulfonylalkyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, eller to substituenter danner en alkylendioksygruppe eller en haloalkylendioksygruppe, eller sammensmeltet til aryl- eller heteroarylgruppen kan være én eller flere sykloalkyl-, aryl-, heterosyklyl- eller heteroarylrester, idet hver av substituentene eventuelt substitueres med én eller flere ytterligere substituenter valgt fra halo, cyano, alkyl, haloalkyl, alkoksy, haloalkoksy, sykloalkyl, heterosyklyl eventuelt substituert med alkyl, aryl, heteroaryl, hydroksyl, alkoksyalkyl, hydroksyalkoksy, alkylamino, alkylsulfonylamino, alkoksykarbonylamino, aminoalkoksy eller alkoksykarbonylaminoalkoksy;
og hvori, når:

R^1, $R^{1'}$, R^2, $R^{2'}$, R^3, $R^{3'}$ er H, og

L^2 er enkeltbinding, og

Ar^1 er et 6-leddet aryl eventuelt substituert med én eller flere grupper valgt fra halo, cyano, C1-C3-alkyl, C1-haloalkyl, og

Ar^2 er en 5- til 6-leddet aryl- eller heteroarylgruppe eventuelt substituert med én eller flere grupper valgt fra halo, C1-C3-alkyl, hydroksyl, metoksy eller sammensmeltet til en aryl- eller heteroarylgruppe eventuelt substituert med én eller flere halo, C1-C3-alkyl, hydroksyl, metoksy,
deretter,

Ar^1 er fenyl, 3-halofenyl, 4-halofenyl, 2,3-diklorfenyl, 2,4-difluorfenyl, 2,5-dihalofenyl, 2,6-difluorfenyl, 2,6-diklorfenyl, 3,4-dihalofenyl, 3,5-dihalofenyl, 3,4,5-trihalofenyl, 2-cyanofenyl, 3-cyanofenyl, 4-cyanofenyl, 2,3-dicyanofenyl, 2,4-dicyanofenyl, 3,5-dicyanofenyl, 3-cyano-4-halofenyl, 4-(C1-C3 alkyl)fenyl, 3,4-di(C1-C3-alkyl)fenyl, 3,5-di(C1-C3-alkyl)fenyl, 4-(C1-haloalkyl)fenyl, og

Ar^2 er 2-(C1-C3-alkyl)tiazol-4-yl, 5-(C1-C3-alkyl)tiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1-C3-alkyl)pyridin-2-yl, 5-(C1-C3-alkyl)pyridin-2-yl, 6-(C1-C3-alkyl)pyridin-2-yl, kinolin-2-yl, isokinolin-3-yl, 8-halokinolin-2-yl, benzotiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzotiazol-2-yl;

med følgende forbehold:
- **Ar^1** er hverken en substituert eller usubstituert pyrazolo[1,5-a]pyridin-2-yl- eller en substituert eller usubstituert pyrazolo[1,5-a]pyrimidin-2-yl-rest; og
forbindelsen med formel I er ingen av:
(2,4-difluorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-klorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
2-(3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-karbonyl)benzonitril;
(2,6-diklorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon,

(2,3-diklorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon,
(2,3-diklorfenyl)(3-(5-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon,
(2,3-diklorfenyl)(3-(6-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon.

2. Forbindelsen ifølge krav **1** som har formel Ib



Ib

og farmasøytisk akseptable salter og solvater derav, hvori
Ar^1, Ar^2, R^1, $R^{1'}$ R^2, $R^{2'}$, R^3, $R^{3'}$ X^1, X^2, er som definert i krav **1.**

3. Forbindelsen ifølge krav **2** som har formel Ic



Ic

og farmasøytisk akseptable salter og solvater derav, hvori a avbilder bindingen som binder **R^1** til piperazinresten, og **Ar^1, Ar^2, R^1, $R^{1'}$, X^1,** o **X^2** er som definert i krav **2.**

4. Forbindelsen ifølge krav **3** valgt fra formlene Id-1, Id-2, Id-3 og Id-4



Id-1 Id-2 Id-3 Id-4

og farmasøytisk akseptable salter og solvater derav, hvori

a avbilder bindingen som binder $\mathbf{R^1}$ til piperazinresten; og

$\mathbf{Ar^2}$, $\mathbf{R^1}$, $\mathbf{X^1}$ og $\mathbf{X^2}$ er som definert i krav **2**; og

$\mathbf{R^4}$, $\mathbf{R^{4'}}$, $\mathbf{R^5}$, $\mathbf{R^{5'}}$ og $\mathbf{R^6}$ er uavhengig valgt fra H, halo, cyano, alkyl, haloalkyl, C3-C6-sykloalkyl, heteroalkyl, heterosyklyl, aryl, heteroaryl, hydroksyl, alkoksy, haloalkoksy, alkoksyalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, karbamoyl, alkylkarbamoyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, eller $\mathbf{R^5}$ sammen med $\mathbf{R^4}$ eller $\mathbf{R^6}$, eller $\mathbf{R^{5'}}$ sammen med $\mathbf{R^{4'}}$ eller $\mathbf{R^6}$ danner en alkylendioksy- eller en haloalkylendioksygruppe, eller $\mathbf{R^5}$ sammen med $\mathbf{R^4}$ eller $\mathbf{R^6}$, eller $\mathbf{R^{5'}}$sammen med $\mathbf{R^{4'}}$ eller $\mathbf{R^6}$ danner en arylrest sammensmeltet til fenylgruppen som de er festet til, idet hver av substituentene eventuelt er substituert med én eller flere ytterligere substituenter valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl; og

$\mathbf{R^7}$ er H eller metyl; og

$\mathbf{R^{7'}}$ er H eller metyl; og

$\mathbf{Ar^4}$ er en sykloalkyl- eller en arylgruppe, idet hver av sykloalkyl- eller arylgruppene eventuelt substitueres med én eller flere grupper valgt fra halo, alkyl, haloalkyl, syklopropyl, haloalkoksy, aryloksy; og

M^1 er N eller C-**R$^{4"}$** hvori **R$^{4"}$** er valgt fra H, halo, cyano, alkyl, haloalkyl, C3-C6-sykloalkyl, heteroalkyl, heterosyklyl, aryl, heteroaryl, hydroksyl, alkoksy, haloalkoksy, alkoksyalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, karbamoyl, alkylkarbamoyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, idet hver av substituentene eventuelt substitueres med én eller flere ytterligere substituenter valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl; og

M^2 er N eller **M^2** er C-**R$^{5"}$** under den forutsetning at **M^1** er N, hvori **R$^{5"}$** er valgt fra H, halo, cyano, alkyl, haloalkyl, C3-C6-sykloalkyl, heteroalkyl, heterosyklyl, aryl, heteroaryl, hydroksyl, alkoksy, haloalkoksy, alkoksyalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, karbamoyl, alkylkarbamoyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, eller **R$^{5"}$** sammen med **R^6** danner en alkylendioksygruppe eller en haloalkylendioksygruppe, eller en arylrest sammensmeltet til pyridinylgruppen som de er festet til, idet hver av substituentene eventuelt substitueres med én eller flere ytterligere substituenter valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl; og

hvori, i formel Id-1 når:

R^1 er H, og

R^4, R$^{4'}$, R^5, R$^{5'}$ og **R^6** er uavhengig valgt fra H, halo, cyano, C1-C3-alkyl, C1-haloalkyl, og

Ar^2 er en 5- til 6-leddet aryl- eller heteroarylgruppe eventuelt substituert med én eller flere grupper valgt fra halo, C1-C3-alkyl, hydroksyl, alkoksy eller sammensmeltet til en arylgruppe eventuelt substituert med én eller flere halo, C1-C3-alkyl, hydroksyl, metoksy

deretter,

R^4, R$^{4'}$, R^5, R$^{5'}$ og **R^6** er H, eller **R^4, R$^{4'}$, R$^{5'}$, R^6** er H og **R^5** er halo, eller **R^4, R$^{4'}$, R^5, R$^{5'}$** er H og **R^6** er halo, cyano, C1-C3-alkyl, C1-haloalkyl, eller **R$^{4'}$, R$^{5'}$, R^6** er H og **R^4, R^5** er halo, eller **R^4, R$^{4'}$, R$^{5'}$** er H og **R^5, R^6** er uavhengig halo, eller **R^4, R$^{4'}$** er H og **R^5, R$^{5'}$, R^6** er halo, og

Ar^2 er 2-(C1-C3-alkyl)tiazol-4-yl, 5-(C1-C3-alkyl)tiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1-C3-alkyl)pyridin-2-yl, 5-(C1-C3-alkyl)pyridin-2-yl, 6-(C1-C3-alkyl)pyridin-2-yl, kinolin-2-yl, isokinolin-3-yl, 8-halokinolin-2-yl, benzotiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzotiazol-2-yl.

5. Forbindelsen ifølge krav **4** valgt fra formlene Ie-1, Ie-2 og Ie-3



Ie-1 Ie-2 Ie-3

og farmasøytisk akseptable solvater derav, hvori

a avbilder bindingen som binder **R^1** til piperazinresten; og

Ar^2, R^1, X^1 og **X^2** er som definert i krav **2**; og

R^5 og **R^6** er uavhengig valgt fra H, halo, cyano, alkyl, syklopropyl, aryl, heteroaryl, idet hver av aryl- og heteroarylgruppene eventuelt substitueres med én eller flere grupper valgt fra halo, alkyl, syklopropyl eller **R^5** og **R^6** danner sammen en fenylrest sammensmeltet til fenylringen som de er festet til; og

R^8, R$^{8'}$, R^9, R$^{9'}$ og **R^{10}** er uavhengig valgt fra H, halo, haloalkyl, syklopropyl eller haloalkoksy, eller **R^8, R$^{8'}$, R^9, R$^{9'}$** er H og **R^{10}** er fenoksy;

M^1 og **M^2** er som definert i krav **4**; og

hvori, i formel Ie-1, når:

R^1 er H, og

R5 og **R6** er uavhengig valgt fra H, halo, cyano, C1-C3-alkyl og

Ar2 er en 5- til 6-leddet aryl- eller heteroarylgruppe eventuelt substituert med én eller flere grupper valgt fra halo, C1-C3-alkyl, hydroksyl, alkoksy eller sammensmeltet til en arylgruppe eventuelt substituert med én eller flere halo, C1-C3-alkyl, hydroksyl, metoksy deretter,

R6 er H og **R5** er H, halo, eller **R5** er H og **R6** er halo, cyano, C1-C3-alkyl, C1-haloalkyl, eller **R5** og **R6** er uavhengig halo, og

Ar2 er 2-(C1-C3-alkyl)tiazol-4-yl, 5-(C1-C3-alkyl)tiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1-C3-alkyl)pyridin-2-yl, 5-(C1-C3-alkyl)pyridin-2-yl, 6-(C1-C3-alkyl)pyridin-2-yl, kinolin-2-yl, isokinolin-3-yl, 8-halokinolin-2-yl, benzotiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzotiazol-2-yl.

6. Forbindelsen ifølge krav **3** valgt fra formlene If-1, If-2, If-3, If-4, If-5, If-6, If-7 og If-8



og farmasøytisk akseptable salter og solvater derav, hvori
a avbilder bindingen som binder **R1** til piperazinresten; og

Ar1, R1, X1 og **X2** er som definert i krav **2**; og

R11, R12, R12' og **R13** er uavhengig valgt fra H, halo, cyano, alkyl, hydroksyalkyl, haloalkyl, C3-C6-sykloalkyl, heteroalkyl, heterosyklyl, aryl, heteroaryl, hydroksyl, alkoksy,

haloalkoksy, alkylamino, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, acylamino, karbamoyl, alkylkarbamoyl, karbamoylalkyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino eller **R^{12}**sammen med **R^{11}** eller **R^{13},** eller **R^{13}** sammen med **R$^{12'}$** danner en alkylendioksygruppe eller en haloalkylendioksygruppe, eller **R^{12}** sammen med **R^{11}** eller **R^{13}** danner en sykloalkyl-, aryl-, heterosyklyl- eller heteroarylrest sammensmeltet til pyridylgruppen som de er festet til, idet hver av gruppene eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy eller hydroksyl; og

Ar^{5} er en heterosyklyl-, aryl-, heteroaryl-, aralkyl-, heteroarylalkyl- eller arylsulfonylalkylgruppe, idet hver av disse eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy, heterosyklyl eventuelt substituert med alkyl, aryl, hydroksyl, alkoksy, alkoksyalkyl, hydroksyalkoksy, alkylamino, alkylsulfonylamino, aminoalkoksy eller alkoksykarbonylaminoalkoksy; og

X^{3} er O eller S; og

R^{14} er H eller metyl; og

Ar^{6} er en heterosyklyl-, aryl- eller heteroarylgruppe, idet hver av disse eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy, aryl eller hydroksyl; og

R^{15} er H eller metyl; og

R^{16} er en heterosyklyl-, aryl- eller heteroarylgruppe, idet hver av gruppene eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy eller hydroksyl;

R^{17} er H, metyl eller **R^{17}** sammen med **R^{16}** danner en sykloalkyl- eller arylrest sammensmeltet til tiazolylgruppen som de er festet til, og danner dermed et sammensmeltet ringsystem, idet det sammensmeltede ringsystemet eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy eller hydroksyl; og

X^{5} er O eller S, eller N-**R^{36}** hvori **R^{36}** er H eller C1-C3-alkyl; og

Ar^{7} er en heterosyklyl-, aryl- eller heteroarylgruppe, idet hver av disse eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy, aryl eller hydroksyl; og

X^{6} er O, S eller N-**R$^{36'}$** hvori **R$^{36'}$** er H eller C1-C3-alkyl; og

R$^{14'}$ er H eller metyl; og

R^{34} er H, alkyl, alkoksyalkyl, hydroksyalkyl, alkoksykarbonylaminoalkyl; og

R^{35} er H, alkyl, alkoksyalkyl, hydroksyalkyl, alkoksykarbonylaminoalkyl; og
hvori

- i formel If-1 når:

R^{1} er H, og

Ar^{1} er et 6-leddet aryl eventuelt substituert med én eller flere grupper valgt fra halo, cyano, C1-C3-alkyl, C1-haloalkyl og

R^{11}, R^{12}, R$^{12'}$ og **R^{13}** er uavhengig valgt fra H, halo, C1-C3-alkyl, hydroksyl, metoksy eller **R^{12}** sammen med **R^{11}** eller **R^{13}**danner en aryl- eller heterosyklyl- eller heteroarylrest sammensmeltet til pyridylgruppen som de er festet til og eventuelt substitueres med én eller flere grupper valgt fra halo, C1-C3-alkyl, metoksy eller hydroksyl,
deretter,

Ar^{1} er fenyl, 3-halofenyl, 4-halofenyl, 2,3-diklorfenyl, 3,4-dihalofenyl, 3,4,5-trihalofenyl, 4-cyanofenyl, 4-(C1-C3-alkyl)fenyl, 4-(C1 haloalkyl)fenyl, og

R^{11}, R^{12}, R$^{12'}$ og **R^{13}** er H, eller **R^{11}, R^{12}, R$^{12'}$** er H og **R^{13}** er halo, C1-C3-alkyl, eller **R^{11}, R$^{12'}$, R^{13}** er H og **R^{12}** er C1-C3-alkyl, eller **R^{12}, R$^{12'}$, R^{13}** er H og **R^{11}** er C1-C3-alkyl, eller **R^{11}, R^{12},**

R$^{12'}$og **R^{13}** sammen med pyridylgruppen som de er festet til, danner en kinolin-2-yl-, isokinolin-3-yl- eller 8-halokinolin-2-yl-rest; og
- i formel If-4 når:

R^{1} er H, og

Ar^{1} er et 6-leddet aryl eventuelt substituert med én eller flere grupper valgt fra halo, cyano, C1-C3-alkyl, C1-haloalkyl og

R^{17} sammen med **R^{16}** danner en sykloalkyl- eller arylrest sammensmeltet til tiazolylgruppen som de er festet til, og danner dermed et sammensmeltet ringsystem, idet det sammensmeltede ringsystemet eventuelt substitueres med én eller flere grupper valgt fra halo, C1-3-alkyl, metoksy eller hydroksyl,

deretter

Ar^{1} er fenyl, 3-halofenyl, 4-halofenyl, 2,3-diklorfenyl, 3,4-dihalofenyl, 3,4,5-trihalofenyl, 4-cyanofenyl, 4-(C1-C3-alkyl)fenyl, 4-(C1 haloalkyl)fenyl, og

R^{17} og **R^{16}** danner sammen med tiazolylgruppen som de er festet til, en benzotiazol-2-yl- eller 4,5,6,7-tetrahydro-1,3-benzotiazol-2-yl-rest.

7. Forbindelsen ifølge krav **6** valgt fra formlene Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 og Ig-8



Ig-1



Ig-2



Ig-3



Ig-4



Ig-5 Ig-6 Ig-7 Ig-8

og farmasøytisk akseptable salter og solvater derav, hvori

a avbilder bindingen som binder **R[1]** til piperazinresten; og

Ar[1], R[1], X[1] og **X[2]** er som definert i krav **2**; og

R[14], R[14'], R[15], R[34], R[35], X[3] X[5] og **X[6]** er som definert i krav **6**; og

R[12'] og **R[13]** er uavhengig valgt fra H, halo, cyano, alkyl, hydroksyalkyl, haloalkyl, sykloalkyl, heteroalkyl, hydroksyl, alkoksy, haloalkoksy, karboksy, alkoksykarbonyl, alkylkarbonyloksy, alkylkarbonylamino, haloalkylkarbonylamino, acylamino, karbamoyl, alkylkarbamoyl, karbamoylalkyl, karbamoylamino, alkylkarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino eller **R[13]**sammen med **R[12']** danner en alkylendioksygruppe eller en haloalkylendioksygruppe, idet hver av gruppene eventuelt substitueres med én eller flere grupper valgt fra halo, cyano, alkyl, haloalkyl, alkoksy, haloalkoksy, hydroksyl eller okso; og

R[18], R[19], R[19'] og **R[20]** er uavhengig valgt fra H, halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy; og

R[21], R[21'], R[22], R[22'] og **R[23]** er uavhengig valgt fra H, halo, cyano, alkyl, haloalkyl, syklopropyl, heterosyklyl eventuelt substituert med alkyl, hydroksyl, alkoksy, haloalkoksy, hydroksyalkoksy, alkylamino, alkylsulfonylamino, aminoalkoksy, alkoksykarbonylaminoalkoksy; og

R[24], R[24'], R[25], R[25'] og **R[26]** er uavhengig valgt fra H, halohaloalkyl, syklopropyl; og

R^{27}, R^{28}, R^{29} og **R^{30}** er uavhengig valgt fra H, halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy; og

$R^{27'}$, $R^{28'}$, $R^{29'}$ og **$R^{30'}$** er fraværende, eller **$R^{27'}$, $R^{28'}$, $R^{29'}$** og **$R^{30'}$**er H under den forutsetning at **R^{28}, R^{29}** og **R^{30}** er H og at **R^{27}** er valgt fra H, klor eller fluor; og

de to bindingene representert av de stiplede linjene i formel Ig-4 er begge fraværende, eller begge er til stede under den forutsetning at **$R^{27'}$, $R^{28'}$, $R^{29'}$** og **$R^{30'}$** er fraværende; og

R^{31}, $R^{31'}$, R^{32}, $R^{32'}$ og **R^{33}** er uavhengig valgt fra H, halo, cyano, alkyl, haloalkyl, syklopropyl, alkoksy, haloalkoksy; og

hvori,

- i formel Ig-1 når:

R^{1} er H, og

Ar^{1} er et 6-leddet aryl eventuelt substituert med én eller flere grupper valgt fra halo, cyano, C1-C3-alkyl, C1-haloalkyl og

$R^{12'}$, R^{13}, R^{18}, R^{19}, $R^{19'}$ and **R^{20}** er uavhengig valgt fra H, halo, C1-3-alkyl, hydroksyl, metoksy,

deretter,

Ar^{1} er fenyl, 3-halofenyl, 4-halofenyl, 2,3-diklorfenyl, 3,4-dihalofenyl, 3,4,5-trihalofenyl, 4-cyanofenyl, 4-(C1-C3-alkyl)fenyl, 4-(C1 haloalkyl)fenyl, og

$R^{12'}$, R^{13}, R^{18}, R^{19}, $R^{19'}$ og **R^{20}** er H, eller **$R^{12'}$, R^{13}, R^{19}, $R^{19'}$, R^{20}** er H og **R^{18}** er fluor, klor, og

- i formel Ig-4 når

R^{1} er H, og

Ar^1 er et 6-leddet aryl eventuelt substituert med én eller flere grupper valgt fra halo, cyano, C1-C3-alkyl, C1-haloalkyl, og

R^{27}, R^{28}, R^{29} og **R^{30}** er uavhengig valgt fra H, halo, C1-3-alkyl, metoksy, og

R$^{27'}$, R$^{28'}$, R$^{29'}$ og **R$^{30'}$** er fraværende eller H under den forutsetning at **R^{28}, R^{29}** og **R^{30}** er H og **R^{27}** er valgt fra H, klor eller fluor,

deretter,
Ar^1 er fenyl, 3-halofenyl, 4-halofenyl, 2,3-diklorfenyl, 3,4-dihalofenyl, 3,4,5-trihalofenyl, 4-cyanofenyl, 4-(C1-C3-alkyl)fenyl, 4-(C1 haloalkyl)fenyl, og

R^{27}, R^{28}, R^{29} og **R^{30}** er H, og

R$^{27'}$, R$^{28'}$, R$^{29'}$ og **R$^{30'}$** er fraværende eller H under den forutsetning at **R^{27}, R^{28}, R^{29}** og **R^{30}** er H.

8. Forbindelsen med formel If-2 ifølge krav **6** som har formel Ih-2



Ih-2

og farmasøytisk akseptable salter og solvater derav, hvori

a avbilder bindingen som binder **R^1** til piperazinresten; og

Ar^1, R^1, X^1 og **X^2** er som definert i krav **2**; og

X^3 er som definert i krav **6**; og

$R^{14"}$ er H eller metyl; og

X^4 er O, CH_2, CF_2, $C(CH_3)_2$, N-(C1-C3 alkyl) N-fenyl; og

R^{36a}, R^{36b}, $R^{36'a}$, R^{37a} og **$R^{37'a}$** er uavhengig valgt fra H, C1-C3-alkyl, alkoksyC1-C3 alkyl.

9. Forbindelsen ifølge krav **3** valgt fra formlene Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7, Ii-8, Ij-1, Ij-2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4, Ik-5, Ik-6, Ik-7, Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii'-6, Ii'-7 og Ii'-8



Ii-1



Ii-2



Ii-3



Ii-4



Ii-5



Ii-6



Ii-7



Ii-8



Ij-1



Ij-2



Ij-3



Ij-4



Ij-5



Ij-6



Ij-7



Ij-8



Ik-1



Ik-2



Ik-3



Ik-4



Ik-5



Ik-6



Ik-7



Ik-8



Ii'-1



Ii'-2



Ii'-3



Ii'-4



Ii'-5



Ii'-6



Ii'-7



Ii'-8

og farmasøytisk akseptable salter og solvater derav, hvori

a avbilder bindingen som binder $\mathbf{R^1}$ til piperazinresten; og

$\mathbf{R^1}$, $\mathbf{X^1}$ og $\mathbf{X^2}$ er som definert i krav **2**; og

$\mathbf{Ar^4}$, $\mathbf{R^4}$, $\mathbf{R^{4'}}$, $\mathbf{R^5}$, $\mathbf{R^{5'}}$, $\mathbf{R^6}$, $\mathbf{R^7}$, $\mathbf{R^{7'}}$, $\mathbf{M^1}$, $\mathbf{M^2}$ er som definert i krav 4; og

$\mathbf{Ar^5}$, $\mathbf{Ar^6}$, $\mathbf{Ar^7}$, $\mathbf{R^{11}}$, $\mathbf{R^{12}}$, $\mathbf{R^{12'}}$, $\mathbf{R^{13}}$, $\mathbf{R^{14}}$, $\mathbf{R^{14'}}$, $\mathbf{R^{15}}$, $\mathbf{R^{16}}$, $\mathbf{R^{17}}$, $\mathbf{R^{34}}$, $\mathbf{R^{35}}$, $\mathbf{X^3}$, $\mathbf{X^5}$, $\mathbf{X^6}$, og er som definert i krav **6.**

10. Forbindelsen ifølge krav **9** valgt fra formlene Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il'-2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7, Il'-8



II-1 II-2 II-3 II-4



II-5 II-6 II-7 II-8



II'-1 II'-2 II'-3 II'-4

II'-5 II'-6 II'-7 II'-8

og farmasøytisk akseptable salter og solvater derav, hvori:

a avbilder bindingen som binder **R^1** til piperazinresten; og

R^1, X^1 og **X^2** er som definert i krav **2**; og

R^4, R$^{4'}$, R^5, R$^{5'}$, R^6, M^1 og **M^2** er som definert i krav **4**; og

R$^{12'}$, R^{13}, R^{14}, R$^{14'}$, R^{15}, R^{18}, R^{19}, R$^{19'}$, R^{20}, R^{21}, R$^{21'}$, R^{22}, R$^{22'}$, R^{23}, R^{24}, R$^{24'}$, R^{25}, R$^{25'}$ R^{26}, R^{27}, R$^{27'}$, R^{28}, R$^{28'}$, R^{29}, R$^{29'}$, R^{30}, R$^{30'}$, R^{31}, R$^{31'}$, R^{32}, R$^{32'}$, R^{33}, R^{34}, R^{35}, X^3, X^5; X^6; og de to bindingene representert av de stiplede linjene er som definert i krav 7.

11. Forbindelsen ifølge krav **10** valgt fra formlene Im-1, Im-2, Im-3, Im-4, Im-5, Im-6, Im-7, Im-8, Im'-1, Im'-2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 og Im'-8



Im-1 Im-2 Im-3 Im-4



Im-5 Im-6 Im-7 Im-8



Im'-1 Im'-2 Im'-3 Im'-4



Im'-5 Im'-6 Im'-7 Im'-8

og farmasøytisk akseptable salter og solvater derav, hvori:

a avbilder bindingen som binder $\mathbf{R^1}$ til piperazinresten; og

$\mathbf{R^1}$, $\mathbf{X^1}$ og $\mathbf{X^2}$ er som definert i krav **2**; og

R^5, R^6, M^1 og **M^2** er som definert i krav **5**; og

$R^{12'}$, R^{13}, R^{14}, $R^{14'}$, R^{15}, R^{18}, R^{19}, $R^{19'}$, R^{20}, R^{21}, $R^{21'}$, R^{22}, $R^{22'}$, R^{23}, R^{24}, $R^{24'}$, R^{25}, $R^{25'}$, R^{26}, R^{27}, $R^{27'}$, R^{28}, $R^{28'}$, R^{29}, $R^{29'}$, R^{30}, $R^{30'}$, R^{31}, $R^{31'}$, R^{32}, $R^{32'}$, R^{33}, R^{34}, R^{35}, X^3, X^5, X^6; og de to bindingene representert av de stiplede linjene er som definert i krav **7.**

12. Forbindelsen ifølge krav **1** valgt fra gruppen som består av:
(4-fluorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-klorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(4-klorfenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3,4-diklorfenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3,4-diklorfenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(5-klorpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(3-(6-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(8-metyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2,4-diklorfenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3,4-diklorfenyl)-1-metyl-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(4-fluorfenyl)(3-(isokinolin-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(3-(4-(trifluormetyl)fenyl)-1H-pyrazol-5-yl)metanon;
(3-(4-fenoksyfenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(8-fluorkinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(8-klorkinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(3-(2-(4-(trifluormetyl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(6-fenylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(4,5,6,7-tetrahydrobenzo[d]tiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(3-(trifluormetyl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(2-(2,3-diklorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(2-(4-klorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

(4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(piperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(4-fenylpiperazin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(2,4-diklorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(2-(3,5-diklorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(6-morfolinopyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(6-(trifluormetyl)pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(3,4-dimetoksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(8-(4-fluorfenyl)-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(3-klorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(8-isopropyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(4-fluorfenyl)(8-metyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(4-fluorfenyl)(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(8-metyl-3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

[1,1'-bifenyl]-4-yl(8-metyl-3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(8-(2-hydroksyetyl)-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(4-fenyltiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(2-klorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(benzo[d]tiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(8,8-dimetyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-3-yl)fenyl)metanon;
(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-3-yl)fenyl)metanon;
(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(2-klorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

[1,1'-bifenyl]-4-yl(3-(2-(2-klorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-(3-(2-(4-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-(4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

[1,1'-bifenyl]-4-yl(8-metyl-3-(4-metyl-2-fenyltiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(2-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

(4-fluorfenyl)(8-metyl-3-(4-metyl-2-fenyltiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

[1,1'-bifenyl]-4-yl(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

[1,1'-bifenyl]-4-yl(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

naftalen-1-yl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(4-klorfenyl)-1-metyl-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(5-(4-klorfenyl)-1-metyl-1H-pyrazol-3-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(8-metyl-3-(5-fenyl-1,2,4-oksadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(8-metyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-(3-(2-(4-fluorfenyl)oksazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(5-fenylpyridin-2-yl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(6-fenylpyridin-3-yl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(2-fenylpyrimidin-5-yl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fenylsykloheksyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
sykloheksyl(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
3-metyl-1-(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-on;
[1,1'-bifenyl]-2-yl(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(furan-3-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(pyrimidin-5-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(9-metyl-9H-karbazol-2-yl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(pyrimidin-2-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(pyrazin-2-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(pyridazin-3-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
4'-(3-(kinolin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-karbonyl)-[1,1'-bifenyl]-4-karbonitril;

1-(4-(3-(kinolin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-karbonyl)fenyl)piperidin-2-on;

(4-morfolinofenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(4-(3,5-dimetyl-1H-pyrazol-1-yl)fenyl)(3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(4-fluorfenyl)tiazol-4-yl)-6-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(4-fluorfenyl)tiazol-4-yl)-5-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3,4-diklorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3,4-difluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-klor-4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(4-klor-3-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(3,4,5-trifluorfenyl)metanon;

(8-metyl-3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(R)-(4-fluorfenyl)(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-[1,1'-bifenyl]-4-yl(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-[1,1'-bifenyl]-4-yl(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-(4-fluorfenyl)(8-metyl-3-(6-fenylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-[1,1'-bifenyl]-4-yl(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-(4-fluorfenyl)(8-metyl-3-(4,5,6,7-tetrahydrobenzo[d]tiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(R)-(3-(2-(2,3-diklorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
R)-(4-fluorfenyl)(8-metyl-3-(2-(4-fenylpiperazin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(3-(2-(2,4-diklorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(R)-(3-(2-(3-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(R)-(4-fluorfenyl)(8-metyl-3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-[1,1'-bifenyl]-4-yl(8-metyl-3-(2-fenyloksazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(4-fluorfenyl)(8-(2-hydroksyetyl)-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(4'-fluor-[1,1-bifenyl]-4-yl)(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-(4-fluorfenyl)(8-metyl-3-(4-fenyltiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(3-(2-(2-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(R)-(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-3-yl)fenyl)metanon;
(R)-(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-(3-(2-(2-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-[1,1'-bifenyl]-4-yl(3-(2-(2-klorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(R)-[1,1'-bifenyl]-4-yl(8-metyl-3-(4-metyl-2-fenyltiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-[1,1'-bifenyl]-4-yl(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-[1,1'-bifenyl]-4-yl(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(S)-(4-fluorfenyl)(8-metyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(4'-fluor-[1,1'-bifenyl]-4-yl)(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(4-fluorfenyl)(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(8-metyl-3-(kinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(S)-(4-fluorfenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(4-fluorfenyl)(8-metyl-3-(2-fenyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(R)-(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(2,4-difluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(5-fenyl-1,2,4-oksadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(3-fenyl-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(5-fenyl-1,2,4-oksadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3-fenyl-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(3-(2,4-difluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(5-fenyl-1H-1,2,4-triazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(5-fenyl-1H-1,2,4-triazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(2-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(2-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-(2-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(3-(2-(2-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3-(2,4-difluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-((4,5-diklor-1H-imidazol-1-yl)metyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-((4,5-diklor-1H-imidazol-1-yl)metyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4'-fluor-[1,1'-bifenyl]-4-yl)metanon;
(3-(2-(4-klorbenzyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

(3-(2-(4-klorbenzyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(p-tolyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(tiofen-2-yl)fenyl)(3-(2-(p-tolyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-(p-tolyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(tiofen-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-(tiofen-2-yl)fenyl)(3-(2-(tiofen-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-(tiofen-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(3-(2-(tiofen-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(((4-klorfenyl)sulfonyl)metyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-(((4-klorfenyl)sulfonyl)metyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(((4-klorfenyl)sulfonyl)metyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4'-fluor-[1,1'-bifenyl]-4-yl)metanon;
(4-fluorfenyl)(3-(2-(2-metoksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(2-metoksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
[1,1'-bifenyl]-4-yl(3-(2-(2-metoksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
[1,1'-bifenyl]-4-yl(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(3-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(3-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-isopropyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(3-(4-fluorfenyl)-1,2,4-oksadiazol-5-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(3-fenyl-1,2,4-tiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(3-fenyl-1,2,4-tiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(4-bromfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4-bromfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(5-metyltiofen-2-yl)fenyl)metanon;
4-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-karbonyl)benzonitril;
[1,1'-bifenyl]-4-yl(3-(3-fenyl-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(2-(pyridin-4-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(kinolin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(1-metyl-3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4-(dimetylamino)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(3-(1-metyl-5-fenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4'-fluor-[1,1'-bifenyl]-4-yl)(3-(3-fenyl-1,2,4-oksadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(pyridin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(4-fluorfenyl)(3-(1-metyl-3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(pyrimidin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(S)-(8-metyl-3-(2-morfolinotiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(pyridin-4-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4-(dimetylamino)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(pyridin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
fenyl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(p-tolyl)metanon;
(S)-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(2-metyltiofen-3-yl)fenyl)metanon;
(R)-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(2-metyltiofen-3-yl)fenyl)metanon;
(3-(2-(pyrazin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
4-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)benzonitril;
(4-fluorfenyl)(3-(2-(pyrazin-2-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(3-(1-metyl-5-fenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(4-morfolinofenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(4-morfolinofenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(4-(4-metylpiperazin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(4-(4-metylpiperazin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(4-(piperidin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(4-(piperidin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(4-(pyrrolidin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(4-(pyrrolidin-1-yl)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(piperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(pyrrolidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(pyrrolidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-(4-metylpiperazin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(4-metylpiperazin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(1-metyl-2-fenyl-1H-imidazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-(dimetylamino)fenyl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(1-(2-metoksyetyl)-3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(1-(2-metoksyetyl)-3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(3-(2-isobutyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(2-(2-metoksyetyl)morfolino)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4,4-difluorpiperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(3-(2-isobutyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(2,5-dimetylmorfolino)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(2-hydroksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4,4-difluorpiperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(2,6-dimetylmorfolino)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(2,2-dimetylmorfolino)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(3-metyltiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(R)-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(3-metyltiofen-2-yl)fenyl)metanon;
(4-fluorfenyl)(3-(2-(2-hydroksyfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(S)-(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(3-metyltiofen-2-yl)fenyl)metanon;
(3-(2-(2-metylmorfolino)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4,4-dimetylpiperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(5-metyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(4,4-dimetylpiperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;
(4-fluorfenyl)(3-(2-(2-(metoksymetyl)piperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
(4-fluorfenyl)(8-metyl-3-(6-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(2-(2-(metoksymetyl)piperidin-1-yl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

tert-butyl (2-(2-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)fenoksy)etyl)karbamat;

(3-(2-(2-(2-hydroksyetoksy)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(2-(2-aminoetoksy)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

N-(4-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)fenyl)metansulfonamid;

(3-(1-(2-hydroksyetyl)-3-fenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(1-(2-hydroksyetyl)-5-fenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

[1,1'-bifenyl]-4-yl(8-metyl-3-(6-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(8-metyl-3-(6-metylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(2,4-difluorfenyl)-5-metyltiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(3-(dimetylamino)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;

(3-(2-(3-(dimetylamino)fenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorfenyl)metanon;

N-(3-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)fenyl)metansulfonamid;

N-(2-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)fenyl)metansulfonamid;

(3-(4-klorfenyl)-1H-pyrazol-5-yl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(4-klorfenyl)-1-metyl-1H-pyrazol-5-yl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(3-(3,4-diklorfenyl)-1-metyl-1H-pyrazol-5-yl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;

(5-(4-klorfenyl)-1-metyl-1H-pyrazol-3-yl)(3-(2-(4-fluorfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)metanon;
tert-butyl (2-(3-fenyl-5-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1H-pyrazol-1-yl)etyl)karbamat;
tert-butyl (2-(5-fenyl-3-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1H-pyrazol-1-yl)etyl)karbamat;
(3-(2-(2-bromfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
(3-(2-(3-bromfenyl)tiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(tiofen-2-yl)fenyl)metanon;
2-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)benzonitril;
3-(4-(7-(4-(tiofen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tiazol-2-yl)benzonitril;
(3-(2-(4-fluorfenyl)tiazol-4-yl)-8-metyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(2-metyltiofen-3-yl)fenyl)metanon;
og farmasøytisk akseptable salter og solvater derav.

13. Farmasøytisk sammensetning som omfatter en forbindelse ifølge ett av kravene **1** til **12** eller et farmasøytisk akseptabelt salt eller solvat derav og minst én farmasøytisk akseptabel bærer, fortynningsmiddel, hjelpestoff og/eller adjuvans.

14. Medikament som omfatter en forbindelse ifølge ett av kravene **1** til **12** eller et farmasøytisk akseptabelt salt eller solvat derav.

15. Forbindelse ifølge ett av kravene **1** til **12** eller et farmasøytisk akseptabelt salt eller solvat derav for anvendelse i behandling og/eller forebygging av depresjon, angst, psykose, schizofreni, psykotiske forstyrrelser, bipolare lidelser, kognitive forstyrrelser, Parkinsons sykdom, Alzheimers sykdom, ADHD, smerte, kramper, fedme, inflammatoriske sykdommer inkludert irritabel tarmsyndrom og inflammatoriske tarmforstyrrelser, emesis, preeklampsi, luftveisrelaterte sykdommer, inkludert kronisk obstruktiv lungesykdom, astma, luftveishyperresponsivitet, bronkokonstriksjon og hoste, reproduseringsforstyrrelser og kjønnshormonavhengige sykdommer, inkludert, men ikke begrenset til, godartet prostatahyperplasi (BPH), metastatisk prostatisk karninom, testikkelkreft, brystkreft,

androgenavhengig akne, mannlig skallethetsmønster, endometriose, unormal pubertet, uterinfibrose, hormonavhengige kreftformer, hyperandrogenisme, hirsutisme, virilisering, polycystisk ovariesyndrom (PCOS), HAIR-AN-syndrom (hyperandrogenisme, insulinresistens og acanthosis nigricans), ovariehypertekose (HAIR-AN med hyperplasi av luteiniserte tekaceller i ovarie stroma), andre manifestasjoner av høye intraovariske androgenkonsentrasjoner (f.eks. follikulær modningsstans, atresi, anovulasjon, dysmenoré, dysfunksjonell livmorblødning, infertilitet), gynekologiske sykdommer, infertilitet og androgenproduserende tumor (viriliserende eggstokk eller adrenal svulst).

16. Forbindelse ifølge ett av kravene **1** til **12** eller et farmasøytisk akseptabelt salt eller solvat derav for anvendelse ved å undertrykke LH-bølgen i assistert oppfatning hos en pasient.

17. Forbindelse ifølge ett av kravene **1** til **12** eller et farmasøytisk akseptabelt salt eller solvat derav for anvendelse i å forårsake mannlig kastrering og hemming av kjønnsdriften hos menn.